Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)
Placed on Senate Legislative Calendar under General Orders. Calendar No. 201.
- Introduced in Senate Formatted Text PDF Formatted XML
- Reported to Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 1852: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-1852/
"S. 1852: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-1852/.
S. 1852, 118th Cong. (2026), https://openamerica.io/bill/118-S-1852/.
[S. 1852: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023](https://openamerica.io/bill/118-S-1852/)